tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tianjin Pharmaceutical Group Files for Bankruptcy Liquidation of Subsidiary

Story Highlights
  • Tianjin Pharmaceutical Da Ren Tang Group operates in the pharmaceutical industry.
  • The company filed for bankruptcy liquidation of its subsidiary due to financial struggles.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Tianjin Pharmaceutical Group Files for Bankruptcy Liquidation of Subsidiary

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) just unveiled an update.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has filed for the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., due to the latter’s inability to repay its debts and insufficient assets to cover liabilities. This move is in accordance with the PRC Enterprise Bankruptcy Law and reflects the financial struggles faced by Shin Poong, which may impact the group’s operations and financial standing.

More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a company incorporated in the People’s Republic of China. The company operates in the pharmaceutical industry, focusing on the manufacturing, processing, and sale of pharmaceutical products such as tablets, capsules, and injectable preparations.

See more data about 2TZ stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1